Home › Funds › Aisling Capital Management LP › SNDX

Aisling Capital Management LP position in SNDX

SYNDAX PHARMACEUTICALS INC · Health Care

Aisling Capital Management LP reported holding 1,316,806 shares of SNDX (SYNDAX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$24.8M, representing 8.27% of its reported portfolio and ranking #2 among its reported holdings. Aisling Capital Management LP has disclosed SNDX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.32M sh
Reported value held$24.76M
Portfolio Weight8.27%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Aisling Capital Management LP's SNDX position evolved

Aisling Capital Management LP first disclosed a stake in SNDX in Q3 2023 at 1,025,000 shares (US$14.9M). The position peaked in Q1 2026 at 1,316,806 shares, worth US$30.8M. Across 13 filings, Aisling Capital Management LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 11 time(s). The most recent filing (Q3 2026) shows 1,316,806 shares valued at US$24.8M. Notable position changes include a 28% increase in Q2 2025 (shares rose 64% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.02M $14.88M New
Q4 2023 1.02M $22.15M Hold
Q1 2024 1.02M $24.39M Hold
Q2 2024 1.02M $21.04M Hold
Q3 2024 1.02M $19.73M Hold
Q4 2024 1.02M $13.55M Hold
Q1 2025 1.02M $12.59M Hold
Q2 2025 1.32M $12.33M Add
Q3 2025 1.32M $20.27M Hold
Q4 2025 1.32M $27.67M Hold
Q1 2026 1.32M $30.76M Hold
Q2 2026 1.32M $28.79M Hold
Q3 2026 1.32M $24.76M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SNDX and 13F data

SNDX (SYNDAX PHARMACEUTICALS INC) is a Health Care company. 39 other funds we track also report a position in SNDX — the largest reported positions include Kynam Capital Management, LP (US$176.0M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$82.6M), Eversept Partners, LP (US$61.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SNDX

All SNDX fund holders →

FAQ

How long has Aisling Capital Management LP held SNDX?

Aisling Capital Management LP has disclosed SNDX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Aisling Capital Management LP's current position in SNDX?

As of Q3 2026, Aisling Capital Management LP holds 1.32M shares of SNDX (SYNDAX PHARMACEUTICALS INC), valued at $24.76M, representing 8.27% of its reported portfolio and ranking #2.

Has Aisling Capital Management LP been buying or selling SNDX?

In the latest 13F filing (Q3 2026), Aisling Capital Management LP held unchanged its position in SNDX. The position peaked in Q1 2026 at 1.32M shares.

Which other funds hold SNDX?

Other major institutional holders of SNDX include Kynam Capital Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Eversept Partners, LP, among 39 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.